CDK4/6 inhibitors in Breast Cancer Therapy

Pankaj Kumar Singh, Manish K. Chourasia, Neelesh Kumar Mehra, Gowthamarajan Kuppusamy

• Publisher: Academic Press
• Year: 2026
• eBook ISBN:
  9780443446122
• Topic: Medicine
• Subtopic: Pharmacology

CDK4/6 inhibitors in Breast Cancer Therapy examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. The book highlights FDA-approved applications of these inhibitors alongside endocrine therapy and explores ongoing research into their potential as neoadjuvant treatments. It provides insights into the drug discovery and development of CDK4/6 inhibitors, covering their molecular mechanisms, pharmacology, and clinical applications. Chapters address their use in mono and adjuvant therapies, as well as challenges in targeting, while also discussing market potential and post-marketing safety issues.This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area. - Provides comprehensive insights into drug discovery and development processes of CDK4/6 inhibitors, detailing the molecular mechanisms and pharmacological aspects relevant to targeted breast cancer therapy - Explores the current clinical applications of CDK4/6 inhibitors, including their use in mono and adjuvant therapies - Discusses market potential and the post-marketing safety issues associated with CDK4/6 inhibitors

Table of contents

• Title of Book
• 1 CDK4/6 inhibitors: drug discovery, development, and classification
• 2 CDK4/6 inhibitors: chemistry, pharmacology and in-silico perspectives
• 3 The molecular mechanics of CDK4/6 inhibitors: resistance pathways and combination strategies
• 4 CDK4/6 inhibitors: Clinical status, patent review, and recent updates
• 5 Resistance and resistance markers of CDK4/6 inhibitors
• 6 The neoteric paradigm of the use of CDK4/6 for breast cancer treatment as mono and adjuvant therapy
• 7 The repurposing era of CDK4/6 in the treatment of various ailments
• 8 Cytotoxic profile, molecular modeling, cell cycle arrest, and apoptosis induced by CDK4/6 inhibitors
• 9 The present day means and challenges in the targeting of CDK4/6 inhibitors
• 10 Market potential, postmarketing safety challenges, and treatment cost of CDK4/6 inhibitors
• 11 CDK4/6 inhibitors: Future perspectives
• Index